Dr. Daniel M. Anderson
Claim this profileAbbott-Northwestern Hospital
Expert in Parotid Gland Cancer
Expert in Cancer
61 reported clinical trials
110 drugs studied
Area of expertise
1Parotid Gland Cancer
Global LeaderStage IV
Stage III
metastatic
2Cancer
Global LeaderStage IV
Stage III
NTRK positive
Affiliated Hospitals
Clinical Trials Daniel M. Anderson is currently running
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
Radium-223 + Cabozantinib
for Kidney Cancer with Bone Metastasis
This phase II trial studies whether adding radium-223 dichloride to the usual treatment, cabozantinib, improves outcomes in patients with renal cell cancer that has spread to the bone. Radioactive drugs such as radium-223 dichloride may directly target radiation to cancer cells and minimize harm to normal cells. Cabozantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving radium-223 dichloride and cabozantinib may help lessen the pain and symptoms from renal cell cancer that has spread to the bone, compared to cabozantinib alone.
Recruiting1 award Phase 216 criteria
More about Daniel M. Anderson
Clinical Trial Related6 years of experience running clinical trials · Led 61 trials as a Principal Investigator · 25 Active Clinical TrialsTreatments Daniel M. Anderson has experience with
- Nivolumab
- Pembrolizumab
- Carboplatin
- Biospecimen Collection
- Paclitaxel
- Cabozantinib S-malate
Breakdown of trials Daniel M. Anderson has run
Parotid Gland Cancer
Cancer
Lung Cancer
Breast Cancer
Prostate Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Daniel M. Anderson specialize in?
Is Daniel M. Anderson currently recruiting for clinical trials?
Are there any treatments that Daniel M. Anderson has studied deeply?
What is the best way to schedule an appointment with Daniel M. Anderson?
What is the office address of Daniel M. Anderson?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.